Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reported a transaction in its own shares as part of its existing buyback programme. On 27 October 2025, acting through BNP Paribas SA, the company purchased 166,000 ordinary shares at prices between 1,632.50p and 1,645.00p, with a volume‑weighted average price of 1,637.64p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 6,448,500 ordinary shares under the programme. Following this purchase, GSK holds 253,913,344 shares in treasury and has 4,061,507,442 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,061,507,442, and the percentage of voting rights attributable to treasury shares is 6.25%.
The filing also lists aggregated venue data (XLON, CHIX, BATE) for the day’s trades and provides media and investor relations contacts.
GSK plc reported that its B7-H3–targeted antibody-drug conjugate, GSK5764227 (GSK'227), received Orphan Drug Designation from the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, a group that includes small‑cell lung cancer. The designation is based on preliminary phase I ARTEMIS-001 data showing durable responses in extensive‑stage SCLC.
This marks the fourth regulatory designation for GSK'227. The program previously secured EMA PRIME for relapsed or refractory ES‑SCLC and two US FDA Breakthrough Therapy Designations for relapsed or refractory ES‑SCLC and late‑line relapsed or refractory osteosarcoma. GSK began a global phase III trial in relapsed ES‑SCLC in August 2025.
SCLC remains a high‑need cancer, with an estimated 250,000 diagnoses and about 200,000 deaths annually worldwide. GSK holds exclusive worldwide rights to GSK'227 outside mainland China, Hong Kong, Macau, and Taiwan.
GSK plc repurchased 555,000 ordinary shares on 24 October 2025 through BNP Paribas SA under its non‑discretionary buyback agreement. The company paid a volume‑weighted average price of 1,619.90p per share, within a range of 1,597.50p to 1,638.50p, and will hold the shares as treasury stock.
Since 30 September 2025, GSK has bought 6,282,500 ordinary shares as part of the programme. After this transaction, GSK holds 253,747,344 shares in treasury and has 4,061,673,442 shares in issue (excluding treasury), which is also the total number of voting rights. The company confirms the percentage of voting rights attributable to treasury shares is 6.25 per cent.
GSK announced US FDA approval of Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma after at least two prior therapies, including a PI and an IMID.
The approval is supported by phase III DREAMM-7, where the BVd combination cut the risk of death by
Blenrep is described as the only anti-BCMA agent accessible across community settings and will be available under a new streamlined REMS. Follow-up for overall survival in DREAMM-7 and -8 continues, with data expected in early
GSK plc repurchased 366,000 ordinary shares on 23 October 2025 under its existing buyback programme via BNP Paribas SA. The purchases were made between 1,640.00p and 1,657.50p per share, with a volume‑weighted average price of 1,648.10p. The shares will be held as treasury shares.
Since 30 September 2025, GSK has purchased 5,727,500 shares. Following this transaction, GSK holds 253,192,344 shares in treasury and has 4,062,224,575 shares in issue (excluding treasury). Total voting rights are 4,062,224,575. The percentage of voting rights attributable to treasury shares is 6.23%.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 248,000 ordinary shares on 22 October 2025 at a volume‑weighted average price of 1,644.38p (range: 1,625.00p–1,655.00p). The shares will be held as treasury shares and the transaction forms part of GSK’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 5,361,500 shares. Following this purchase, GSK holds 252,826,344 shares in treasury and has 4,062,590,575 shares in issue (excluding treasury), which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is 6.22%.
GSK reported positive pivotal phase III results for a next‑generation, low‑carbon version of its Ventolin (salbutamol) metered dose inhaler using propellant HFA‑152a. The data show therapeutic equivalence and a comparable safety profile to the current HFA‑134a formulation, supporting regulatory submissions with launch expected from 2026.
GSK notes approximately 300 million salbutamol MDIs are sold globally each year and that, if approved, the new inhaler has the potential to reduce greenhouse gas emissions by 92% per inhaler. The company added that its salbutamol MDI currently accounts for close to 45% of its total global carbon footprint.
GSK plc reported a share buyback transaction executed via BNP Paribas SA on 21 October 2025, purchasing 250,000 ordinary shares at prices between 1,635.00p and 1,650.00p, with a volume-weighted average price of 1,642.48p. The shares will be held as Treasury shares and the purchase forms part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 5,113,500 ordinary shares. Following this transaction, GSK holds 252,578,344 shares in treasury and has 4,062,838,575 ordinary shares in issue (excluding treasury), which is also the total number of voting rights. GSK confirmed that treasury-held ordinary shares represent 6.22% of voting rights.
GSK plc filed a Form 6-K announcing headline results from the INFRONT-3 trial of latozinemab in frontotemporal dementia due to progranulin mutation (FTD-GRN). The drug achieved a statistically significant effect on the biomarker co-primary endpoint, increasing plasma progranulin (PGRN), but did not show benefit on the clinical co-primary endpoint of slowing FTD-GRN progression. Secondary and exploratory endpoints also did not show treatment-related effects. Preliminary safety data have not highlighted major concerns, and deeper analyses are ongoing.
Based on these results, GSK will discontinue the open-label extension portion of INFRONT-3 and the continuation study for latozinemab. Full results will be presented at an upcoming medical congress. GSK and Alector have collaborated on progranulin-elevating antibodies since July 2021, sharing development responsibilities and costs after Phase 2 proof-of-concept.
GSK reported that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of a new prefilled syringe presentation for Shingrix (Recombinant Zoster Vaccine). After approval by the European Commission, expected in December 2025, the ready-to-use format would eliminate reconstitution of two separate vials, simplifying administration for healthcare professionals.
Shingrix has been approved in the EU since 2018 for adults 50+ and since 2020 for adults 18+ at increased risk of herpes zoster. The positive opinion is based on data confirming technical comparability between the prefilled syringe and the current presentation. Shingles affects approximately 1.7 million people in Europe each year.